New Products: InVitae's Hereditary Pancreatic Cancer Test; Enzymatics' Archer FusionPlex; More | GenomeWeb

InVitae has launched a hereditary pancreatic cancer panel that covers 17 genes related to pancreatic cancer and the option of adding two genes related to hereditary pancreatitis. The test costs $1,500 in the US and has a turnaround time of three weeks.


Enzymatics has updated its Archer FusionPlex ALK, RET, ROS1 Panel to now include select point mutations in ALK and RET that confer resistance to crizotinib.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Cell this week: phosphoproteomic patterns in prostate cancer, effect of gene expression on fitness in yeast, and more.

Scripps Research Institute investigators peer back at the RNA world.

Being born premature shouldn't mean infants with high blood sugar levels don't undergo genetic testing for neonatal diabetes, a study in Pediatrics says.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.